AMY SCHEFLER to Ranibizumab
This is a "connection" page, showing publications AMY SCHEFLER has written about Ranibizumab.
Connection Strength
1.301
-
Randomized Trial of Monthly Versus As-Needed Intravitreal Ranibizumab for Radiation Retinopathy-Related Macular Edema: 1-Year Outcomes. Am J Ophthalmol. 2020 08; 216:165-173.
Score: 0.680
-
Morphological Biomarkers Related to Visual Acuity in Patients With Radiation Retinopathy Treated With Intravitreal Ranibizumab. Ophthalmic Surg Lasers Imaging Retina. 2024 May; 55(5):255-262.
Score: 0.223
-
Randomized Trial of Treat-and-Extend Intravitreal Aflibercept for Radiation Retinopathy: 1-Year Outcomes. Invest Ophthalmol Vis Sci. 2023 Jun 01; 64(7):35.
Score: 0.211
-
Two-year results for ranibizumab for radiation retinopathy (RRR): a randomized, prospective trial. Graefes Arch Clin Exp Ophthalmol. 2022 Jan; 260(1):47-54.
Score: 0.187